The Role of Finasteride in the Management of Androgenetic Alopecia in Male: A Narrative Review

Tumkur, Anil; Ern, Charmine Caryn Teo Cher; Shuang, Chang Ching; Yong, Amilia Chai Hui; Yee, Chan Poh; Leen, Chai Tze; Lock, Lee Kah; Singh, Nermesh

doi:10.5530/ijopp.13.1.2

Cited by 2 publications

(8 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,56 Finasteride does not affect T levels or binding of DHT to AR and therefore does not possess androgenic, antiandrogenic, estrogenic or antiestrogenic, or progestational or steroid hormone-related properties. 56,57 Pharmacokinetics Finasteride when taken orally has a mean half-life of approximately 6 hours, mandating a daily dosage to maintain uniform blood levels. Extensive hepatic metabolism is by the cytochrome P450 enzyme system, specifically CYP3A4 enzyme subfamily.…”

Section: What We Know About Androgens and Mphlmentioning

confidence: 99%

“…Although various dosages ranging from 0.01 mg to 5 mg/day have been tried, 1 mg dosage has been found to be optimal. 57 Finasteride has level 1 evidence for efficacy to prevent progression and improve hair loss in MPHL. 1,4,19,20,32,54,[56][57][58][59] Studies have revealed that the hair count and weight start show increase by approximately 6 months and the improvement continues at least for up to 5 years.…”

Section: What We Know About Androgens and Mphlmentioning

confidence: 99%

“… 1 56 Finasteride does not affect T levels or binding of DHT to AR and therefore does not possess androgenic, antiandrogenic, estrogenic or antiestrogenic, or progestational or steroid hormone-related properties. 56 57 …”

Section: Oral Minoxidilmentioning

confidence: 99%

“…Finasteride does not have any major drug interactions 56 58 but drugs like erythromycin or rifampicin, which impact CYP3A4 enzyme, should be used carefully with finasteride, and the authors recommend evaluation of liver function before starting treatment. 57 Finasteride is recommended in the dosage of 1 mg daily for treatment of MPHL. Although various dosages ranging from 0.01 mg to 5 mg/day have been tried, 1 mg dosage has been found to be optimal.…”

Section: Oral Minoxidilmentioning

confidence: 99%

“…Although various dosages ranging from 0.01 mg to 5 mg/day have been tried, 1 mg dosage has been found to be optimal. 57 …”

Section: Oral Minoxidilmentioning

confidence: 99%

See 4 more Smart Citations

Pharmacological Management of Pattern Hair Loss

Sattur

2021

Indian J Plast Surg

View full text Add to dashboard Cite

Pattern hair loss (PHL) is a condition that worsens with time and the only way it can be slowed down is with pharmacological intervention. Pharmacological treatments for PHL, from an evidenced-based perspective with respect to safety and efficacy, are limited to only two drugs, minoxidil and finasteride. However, there are a host of drugs being used, off-label with limited evidence. This article attempts to review the literature on this topic, and the authors add to this, with their experience of over two decades on incorporating pharmacologic treatments along with hair transplantation in their management of PHL.

show abstract

Section: What We Know About Androgens and Mphlmentioning

confidence: 99%

Section: What We Know About Androgens and Mphlmentioning

confidence: 99%

Section: Oral Minoxidilmentioning

confidence: 99%

Section: Oral Minoxidilmentioning

confidence: 99%

“…Although various dosages ranging from 0.01 mg to 5 mg/day have been tried, 1 mg dosage has been found to be optimal. 57 …”

Section: Oral Minoxidilmentioning

confidence: 99%

See 3 more Smart Citations

Pharmacological Management of Pattern Hair Loss

Sattur

2021

Indian J Plast Surg

View full text Add to dashboard Cite

show abstract

Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects

Estill,

Ford,

Omeira

et al. 2023

Georgetown Medical Review

View full text Add to dashboard Cite

Finasteride and dutasteride are 5-α-reductase inhibitors (5-ARIs) used to treat androgenetic alopecia (AGA). This review evaluates the efficacy of 5-ARIs for treatment of men with AGA and the potential adverse effects on reproduction including sexual dysfunction, infertility, and teratogenicity. A broad literature review was conducted to search for publications on 5-ARI treatment in men with AGA. Hair counts, hair growth assessments, sexual adverse effects (erectile dysfunction, ejaculatory dysfunction, and decreased libido), change in sperm parameters (decreased sperm count, semen volume, sperm motility), and teratogenic drug concentration levels in semen were the measured outcomes of studies included in this literature review. Both finasteride and dutasteride are effective at treating hair loss in male AGA, with studies finding dutasteride was more efficacious than finasteride. Many studies reported sexual adverse effects of 5-ARIs that are uncommon and resolve spontaneously, although there remains no consensus with respect to the presence, severity, and duration of sexual adverse effects. 5-ARIs may have a negative impact on spermatogenesis although the clinical significance of this is unclear and discontinuation of these medications results in improved sperm parameters for most patients. Teratogenicity after paternal exposure is unlikely due to the low concentration of 5-ARIs absorbed in semen. Further research is needed to evaluate the effects of 5-ARI use on reproduction.

show abstract

The Role of Finasteride in the Management of Androgenetic Alopecia in Male: A Narrative Review

Cited by 2 publications

References 56 publications

Pharmacological Management of Pattern Hair Loss

Pharmacological Management of Pattern Hair Loss

Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects

Contact Info

Product

Resources

About